CP
SPRB

Caligan Partners’s Spruce Biosciences SPRB Stock Holding History

Caligan Partners’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,514
Closed -$1.79M – 35
2025
Q4 		$1.79M Buy
+20,514
New +$2.2M 0.15% 23

Other funds holding SPRB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Caligan Partners's SPRB Position: Q1 2026 in Review

Caligan Partners sold out of Spruce Biosciences (SPRB) in Q1 2026, closing a stake of 20,514 shares — an estimated $1.79M sold.

Caligan Partners first reported a position in SPRB in Q4 2025 and held it in 1 quarter. The position peaked at $1.79M in Q4 2025. 32 funds tracked by Wall St. Rank hold SPRB as of Q1 2026.

  • Caligan Partners reported no remaining Spruce Biosciences position as of Q1 2026 after selling out during the quarter.
  • Caligan Partners sold 20,514 Spruce Biosciences shares in Q1 2026, an estimated $1.79M.
  • Caligan Partners first reported a position in Spruce Biosciences in Q4 2025 and held it in 1 quarter.
  • Caligan Partners's Spruce Biosciences position peaked at $1.79M in Q4 2025.
  • 32 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.